Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung…(ENSIGN) | Phase 2 | terminated | Jul 13, 2016 | Eric Bernicker, MD | Lack of funding | Funding |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04427306 | Neoadjuvant T-VEC in High Risk Early Melanoma | Phase 2 | suspended | Jun 11, 2020 | University of California, Davis | low enrollment | Enrollment / accrual |
| NCT03430947 | Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma…(RadioCoBRIM) | Phase 2 | terminated | Feb 13, 2018 | Technische Universität Dresden | Due to insufficient recruitment, the clinical trial was terminated prematurely | Enrollment / accrual |
| NCT05299580 | "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma… | Phase 2 | withdrawn | Mar 29, 2022 | Fondazione Melanoma Onlus | lack of enrollment | Enrollment / accrual |
| NCT02740920 | Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as… | Phase 2 | terminated | Apr 15, 2016 | Canadian Cancer Trials Group | not stated | Not stated |
| NCT05677373 | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in… | Phase 1 / Phase 2 | withdrawn | Jan 10, 2023 | Alliance for Clinical Trials in Oncology | The drug company supporting this trial has withdrawn support, including the ability to provide… | Sponsor / business decision |
| NCT05266430 | Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque…(IL) | — | terminated | Mar 4, 2022 | Aura Biosciences | Sponsor Decision - Low Enrollment | Enrollment / accrual |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Phase 2 | terminated | Apr 22, 2016 | Rutgers, The State University of New Jersey | Study Complete | Other (stated, no rule matched) |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | — | terminated | Dec 30, 2020 | Aristotle University Of Thessaloniki | Due to COVID-19 | COVID-19 / pandemic |
| NCT02203604 | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That… | Phase 2 | terminated | Jul 30, 2014 | CINJRegulatory | Insufficient rate of accrual | Enrollment / accrual |
| NCT04577729 | The IRMI-FMT Trial | N/A | terminated | Oct 8, 2020 | Medical University of Graz | Agreement with project partner prematurely cancelled. | Other (stated, no rule matched) |
| NCT00104884 | FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | Phase 2 | terminated | Mar 4, 2005 | ECOG-ACRIN Cancer Research Group | The study was terminated on May 17, 2006 due to slow accrual. | Enrollment / accrual |
| NCT01559818 | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study… | Phase 1 / Phase 2 | terminated | Mar 21, 2012 | Immodulon Therapeutics Ltd | Sponsor considered no further meaningful data was being collected, nor were likely to be collected… | Other (stated, no rule matched) |
| NCT03060356 | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | Early Phase 1 | terminated | Feb 23, 2017 | University of Pennsylvania | Halt in funding | Funding |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT05561491 | A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced… | Phase 2 | withdrawn | Sep 30, 2022 | Targovax Oy | Strategic reasons | Sponsor / business decision |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT04987996 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell… | Phase 2 | withdrawn | Aug 3, 2021 | Providence Health & Services | Study withdrawn due to lack of supply of one of the investigational agents. | Drug supply |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | Phase 1 / Phase 2 | terminated | Aug 20, 2018 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT04703426 | Sargramostim (GM-CSF) + PD-1 | Phase 2 | withdrawn | Jan 11, 2021 | Dana-Farber Cancer Institute | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Nov 10, 2016 | Asana BioSciences | reformulation | Other (stated, no rule matched) |
| NCT05848219 | Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated… | — | terminated | May 8, 2023 | Novartis Pharmaceuticals | Company decision | Sponsor / business decision |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab…(PIVOT-12) | Phase 3 | terminated | Jun 1, 2020 | Nektar Therapeutics | (Sponsor decision) | Sponsor / business decision |
| NCT01995344 | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment(METILDA) | Phase 2 | terminated | Nov 26, 2013 | The Christie NHS Foundation Trust | Withdrawal of funding | Funding |
| NCT05234437 | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV… | Phase 2 | terminated | Feb 10, 2022 | QBiotics Group Limited | Insufficient Patient Recruitment Rates | Enrollment / accrual |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | Phase 2 | terminated | Feb 4, 2014 | NewLink Genetics Corporation | Withdrawal of IND | Other (stated, no rule matched) |
| NCT04834973 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV… | Phase 1 / Phase 2 | terminated | Apr 8, 2021 | QBiotics Group Limited | Insufficient Patient Recruitment Rates | Enrollment / accrual |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma… | Phase 2 | withdrawn | Aug 11, 2022 | Bristol-Myers Squibb | Replaced it with another clinical trial | Other (stated, no rule matched) |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03878719 | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With… | Phase 1 | terminated | Mar 18, 2019 | Pfizer | The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and… | Safety / toxicity |
| NCT00667953 | Study of Temzolomide and Gleevec in Advanced Melanoma | Phase 1 / Phase 2 | terminated | Apr 28, 2008 | Abramson Cancer Center at Penn Medicine | Difficulty enrolling subjects | Enrollment / accrual |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal… | Phase 1 / Phase 2 | terminated | May 13, 2016 | Calithera Biosciences, Inc | lack of efficacy | Efficacy / futility |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | Phase 1 | terminated | Aug 29, 2017 | Advaxis, Inc. | Business decision | Sponsor / business decision |
| NCT04759846 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | Phase 1 | withdrawn | Feb 18, 2021 | Pierre Fabre Medicament | no recruitment | Enrollment / accrual |
| NCT02591654 | MRI and PET to Assess Pembrolizumab Response(MPAK) | Early Phase 1 | terminated | Oct 29, 2015 | Columbia University | Poor enrollment | Enrollment / accrual |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway… | Phase 1 | terminated | Nov 18, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02052193 | Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma… | Phase 2 | terminated | Jan 31, 2014 | University Hospital Tuebingen | Second cohort not opened because Simon-Two\_Step model failed | Other (stated, no rule matched) |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT02414750 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma(REPOSIT) | Phase 2 | terminated | Apr 13, 2015 | Netherlands Working Group on Immunotherapy of Oncology | Slow accrual and changing treatment landscape | Enrollment / accrual |
| NCT03464604 | Melanoma Accuracy Study; Phase 2 | — | terminated | Mar 14, 2018 | Nova Scotia Health Authority | COVID forced the termination of this study. No impact on participants already enrolled. | COVID-19 / pandemic |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated… | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Innovent Biologics (Suzhou) Co. Ltd. | Sponsor Strategy | Sponsor / business decision |
| NCT00945269 | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating… | Phase 1 / Phase 2 | terminated | Jul 24, 2009 | Fred Hutchinson Cancer Center | ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer be… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 21, 2023source: clinicaltrials